Trial Profile
A Multicenter, Prospective, Non-interventional, Cohort Study to Evaluate the Safety and Effectiveness of Low Dose Edoxaban in Patients With Non-valvular Atrial Fibrillation (NVAF), Who Are Applicable to Any of the Dose Reduction Criteria
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms LEDIOS
- 19 Jun 2018 New trial record